CAN
MCRB icon

Claraphi Advisory Network’s Seres Therapeutics MCRB Stock Holding History

Claraphi Advisory Network’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,282
Closed -$83K – 418
2019
Q2 		$83K Buy
+1,282
New +$122K 0.05% 234

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Claraphi Advisory Network's MCRB Position: Q3 2019 in Review

Claraphi Advisory Network sold out of Seres Therapeutics (MCRB) in Q3 2019, closing a stake of 1,282 shares — an estimated $83K sold.

Claraphi Advisory Network first reported a position in MCRB in Q2 2019 and held it in 1 quarter. The position peaked at $83K in Q2 2019. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2019.

  • Claraphi Advisory Network reported no remaining Seres Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Claraphi Advisory Network sold 1,282 Seres Therapeutics shares in Q3 2019, an estimated $83K.
  • Claraphi Advisory Network first reported a position in Seres Therapeutics in Q2 2019 and held it in 1 quarter.
  • Claraphi Advisory Network's Seres Therapeutics position peaked at $83K in Q2 2019.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2019.

Based on Claraphi Advisory Network's 13F filing for Q3 2019, filed 8 Nov 2019.